nach oben

Erschienen in:

01.06.2019 | Case report

Decitabine

Complete molecular response (unexpected therapeutic benefit) in acute promyelocytic leukemia following decitabine monotherapy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

A 77-year-old woman experienced complete molecular response (unexpected therapeutic benefit) in acute promyelocytic leukaemia (APL) following treatment with decitabine. …

Abboud R, et al. Serendipity: Decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia. Haematologica 104: e170-e173, No. 4, 31 Mar 2019. Available from: URL: http://doi.org/10.3324/haematol.2018.209478 - USA

Titel: Decitabine
Complete molecular response (unexpected therapeutic benefit) in acute promyelocytic leukemia following decitabine monotherapy: case report
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63977-8

Springer Medizin

Decitabine

Complete molecular response (unexpected therapeutic benefit) in acute promyelocytic leukemia following decitabine monotherapy: case report

Excerpt

Weitere Artikel der Ausgabe 1/2019

Vedolizumab

Multiple drugs

Immunomodulators/immunosuppressants

Fingolimod

Immune-globulin/mycophenolate/prednisone

Ibuprofen/paracetamol

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Vedolizumab

Multiple drugs

Immunomodulators/immunosuppressants

Fingolimod

Immune-globulin/mycophenolate/prednisone

Ibuprofen/paracetamol